4F-MDMB-BINACA Wikipedia - Versionsgeschichte

WillyHuonDeKerma am 2. Juli 2026 um 15:36 Uhr

2026-07-02T15:36:40Z

AzucenaDrennen am 2. Juli 2026 um 15:23 Uhr

2026-07-02T15:23:49Z

CathleenBwc: Die Seite wurde neu angelegt: „Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation…“

2026-06-29T14:53:22Z

Die Seite wurde neu angelegt: „Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation…“

Neue Seite

Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14, B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites. The presence of the product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA. Fig. 2. The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F-MDMB-BINACA, suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to their precursor ions, product ions, and fragmentation patterns (Fig. 1). Traditional in-vivo metabolism studies to generate human metabolites of drugs relied heavily on the use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid. Fig. 1. This outcome was anticipated since CES-mediated hydrolysis is commonly [https://cannabinoidsrc4f-adb.com/ JWH-210 powder] reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in 16/20 urine samples (Table 2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m/z 235, indicating loss of sulfate, confirmed the identity of the sulfation metabolite. Fungus C. elegans Concentrations of 4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20 A limitation of this case report is that we did not have a urine sample available for additional NPS testing. Point-of-care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines and methadone. THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e-cigarettes, while crack cocaine is hard to vaporise. A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours . Data availability Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patient. Data availabili LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden JWH-210 powder headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl

← Nächstältere Version		Version vom 2. Juli 2026, 15:36 Uhr
Zeile 1:		Zeile 1:
−	~~When clinical presentation and/or initial DOA testing results~~ are ~~inconclusive~~, ~~additional testing with LC-QTOF-MS can be valuable and~~ is ~~recommended. SCRAs and other NPS may~~ not be detected by ~~point-of-care DOA~~ tests. ~~In this case,~~ the ~~point-~~of~~-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC<br><br>4~~. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (~~Gatch et al.~~, ~~2016~~)~~, and 5F-AMB produced sustained vocalization~~ and ~~convulsions in rats~~ (~~Gatch et al.~~, ~~2018~~). All ~~of the synthetic cannabinoids tested in the present study fully substituted~~ for ~~the discriminative stimulus effects of Δ9-THC~~. ~~Subsequently, a one~~-~~way analysis of variance~~ was ~~conducted on horizontal activity counts for~~ the ~~30-min period~~ of ~~maximal effect, and planned comparisons~~ were ~~conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance~~, ~~with dose as a between groups factor and time as a within subject factor~~, ~~was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects~~ and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>~~Michael B Gatch~~ <br>~~Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration.~~ Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in ~~3 of 8 mice (data not shown)~~. ~~Substantial depressant effects~~ were ~~observed within~~ the ~~first 10 min, and maximal~~ depression ~~was observed between 10–40 min and lasted up to 2~~.~~5 to 3 h at~~ the ~~[https://cannabinoidsrc4f-adb~~.~~com/ adb butinaca] highest dose tested (0~~.5 mg/kg~~).<br>Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2~~ (~~Wiley~~ et al., ~~2016~~), ~~and~~ a ~~compound from the present study, 5F-MDMB-PINACA,~~ was ~~found to activate midbrain dopamine neurons, but not serotonin neurons~~ (~~Asaoka~~ et al., ~~2016~~)~~. As previously mentioned~~, ~~all~~ of the ~~compounds tested in the present study (MDMB~~-~~PINACA~~, ~~MDMB~~-~~CHMICA, MDMB-FUBINACA, ADB-FUBINACA~~, and ~~AMB~~-~~FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these~~ compounds ~~will produce Δ9~~-~~THC-like~~ effects~~, including abuse liability~~. ~~Tremors were not observed following AMB~~-~~FUBINACA during the drug discrimination study~~, ~~but the maximum dose tested was only 0.~~1 ~~mg/kg~~, ~~which is 10-fold lower~~ than ~~the dose that produced tremors in the mic~~<br><br>~~Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans~~ <br>~~This might be due to the low activity of numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite of 4F~~-~~MDMB-BINACA in abundance but the rest of the metabolites were found in~~ a ~~small amount~~. ~~Elegans~~ and ~~HLM models detected all of the~~ in-~~vivo metabolites (100%)~~, ~~whilst HepG2 cells detected 7 out of~~ the ~~8 in-vivo metabolites (87~~.~~5%)~~. ~~Hence~~, ~~structural elucidation could not be confirmed unless~~ a ~~reference standard is made availabl~~<br><br><br>The ~~same procedure was then applied~~ to the ~~mice once every day for 5 days~~. It was ~~considered~~ as ~~coordination disturbance when mice fell from~~ the ~~test apparatus within 2 min~~. ~~Mice that remained their position~~ on the ~~running apparatus at 10 rpm for at least 2 min were selected for further evaluation~~.<br>~~Table of Conten~~<br><br>~~In the present study~~, ~~we performed various methods based on animal behavioral testing including FOB test for general behavioral observation~~, ~~rotarod test, locomotor~~ activity ~~test for motor function evaluation~~, and ~~water-maze test for learning/memory evaluatio~~<br><br><br>~~A limitation~~ of ~~this case report is that we did not have~~ a ~~urine sample available for additional NPS testing~~. ~~Point~~-of-care DOA ~~tests using~~ urine ~~to screen for misuse~~ of ~~multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines~~ and ~~methadone. THC~~, ~~methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under~~ the ~~temperature~~ of ~~current~~ e-cigarettes, ~~while crack cocaine is hard to vaporise. A systematic review including data of 114 patients~~ of ~~which the majority was intoxicated due to~~ SCRA ~~smoking revealed that 45 % of the patients who present at the ER after an~~ intoxication ~~due to SCRA smoking recovered within 24 hours~~ .<br>Data availability <br>~~Moreover~~, ~~a study conducted in~~ the ~~United Kingdom investigated components~~ of e-~~liquids~~ in ~~112 samples originating from prisoners, teenagers~~ and ~~test purchases of commercially available e~~-~~cigarettes taken between 2014 and 2021~~ . ~~This is the first case report~~ that ~~describes~~ the ~~toxicological symptoms of vaping~~ ADB-BUTINACA. ~~Results~~ of ~~the~~ DOA test (~~including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants~~) ~~were available within 30 minutes and were all negative~~. ~~We report~~ a ~~case of an involuntary intoxication of~~ the ~~SCRA ADB-BUTINACA after vaping. There are several pitfalls in~~ the ~~detection~~ of ~~SCRA in samples taken from~~ the ~~patien~~	+	As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br><br>Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch et al., 2018), and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound<br><br><br>JWH-210 Chemical Powder offers a reliable solution for laboratories seeking a compound that meets stringent requirements. Researchers often require compounds that are consistent and dependable, and this product delivers on both fronts. Whether used in small-scale experiments or larger research projects, the compound maintains its integrity under recommended storage conditions. This ensures ease of handling and precise measurement during laboratory use. Each batch undergoes detailed verification to ensure purity, consistency, and accuracy, making it suitable for controlled experimental environments. This study was supported by a grant (13181MFDS654) of the National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Republic of Kore<br><br><br>Demographic and clinical features are recorded and blood and/or urine samples analysed using high-resolution accurate mass liquid chromatography-mass spectrometry. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Second, we could not [https://cannabinoidsrc4f-adb.com/ JWH-210 powder] retrieve further detailed information about the e-cigarette that was used by the patient such as the label or the region of origin. Whether a recreational drug can be administered via vaping, depends on whether the drug becomes volatile under the evaporation temperature of the e-cigarette. Of these samples, 22 contained one or more SCRAs, THC was only detected in 11 samples, only one contained cannabidiol and 6 contained a mixture of THC and cannabidiol. There is difficulty in finding the right information about the NPS, defining their potency and confirmation of their existence in e-liquids or urine samples.<br>Data availabili<br><br><br>Acute kidney damage and even kidney failure have been reported following use of synthetic cannabinoids (Davidson, et al., 2017). One recent study has looked at other mechanisms of action in some of the older synthetic cannabinoids and reported that some produced varying amounts of activity at sites which are related to cardiotoxicity and heart disease (Wiley et al., 2016). It is not known whether the increased toxicity is due only to activation of CB1 cannabinoid receptors more strongly than Δ9-THC or whether these "super-strength" cannabinoids produce effects at other receptors. A major cause of concern is that some of the more recently seen synthetic cannabinoids are more likely to produce extremely toxic effects than the older synthetics (Tai and Fantegrossi, 2017<br><br><br>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .<br>Data availability <br>The intensity is plotted against the retention time for both chromatograms, demonstrating the JWH-210 powder presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom

← Nächstältere Version		Version vom 2. Juli 2026, 15:23 Uhr
Zeile 1:		Zeile 1:
−	~~Product ions detected at m~~/~~z 302, 217~~, and ~~145 (B2) confirmed that tert~~-~~leucine and indazole moieties remained unchanged, leading to the structure elucidation~~ of ~~a hydroxy~~-~~functional group at the 4-position of the butyl side chain by oxidative defluorination~~. ~~The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14~~, ~~B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of~~ the ~~ester hydrolysis plus monohydroxylated metabolites. The presence of the product ion m/z 320, likely formed from a loss~~ of ~~carbon dioxide, indicated monohydroxylation at the tert~~-~~leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining~~ the ~~hydrolysis of methyl ester from 4F~~-~~MDMB-BINACA.~~<br>~~Fig. 2~~. <br>~~The precursor ion m/z 396~~ (~~B10~~, ~~B12/B15~~) ~~was 32 Da higher than the parent drug~~, 4F-~~MDMB-BINACA~~, ~~suggesting the addition of two hydroxy groups~~. All the ~~below explanations~~ for ~~transformations into metabolites are based on~~ the ~~data shown in Fig~~. ~~Metabolites were identified according to their precursor ions~~, ~~product ions, and fragmentation patterns (Fig. 1). Traditional in~~-~~vivo metabolism studies to generate human metabolites~~ of ~~drugs relied heavily~~ on the ~~use~~ of ~~whole animal model systems~~, ~~which are expensive, limited by drug administration amount, influenced by species variation~~ and ~~faced by many ethical issues~~. ~~Eight in~~-~~vivo metabolites tentatively identified were mainly products~~ of ~~ester hydrolysis~~ with ~~or without additional dehydrogenation~~, N-~~dealkylation, monohydroxylation~~ and ~~oxidative defluorination with further oxidation~~ to ~~butanoic acid~~.<br>~~Fig. 1.~~ <br>~~This outcome~~ was ~~anticipated since CES~~-~~mediated hydrolysis is commonly~~ [https://cannabinoidsrc4f-adb.com/ ~~JWH-210 powder~~] ~~reported as the major metabolic pathway among the SCBs impacting the terminal ester group~~ . ~~Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m~~/~~z 350~~). ~~Both ester hydrolysis followed by oxidative defluorination to butanoic acid~~ (B4, ~~m/z 362~~) and ~~monohydroxylation at tert~~-~~leucine moiety~~ (B8, ~~m/z 366~~) ~~metabolites were found~~ in ~~16/20 urine samples~~ (~~Table 2~~). ~~A In~~-~~vitro metabolites~~ observed ~~in common among respective seven most abundant metabolites in b C~~. ~~The product ion detected at m~~/~~z 235~~, ~~indicating loss of sulfate, confirmed~~ the ~~identity of~~ the ~~sulfation metabolite.~~<br>~~Fungus C.~~ elegans <br>~~Concentrations~~ of 4F-MDMB-BINACA in the ~~postmortem blood samples~~ were 2.50 and ~~2.34 ng/mL~~, ~~which are~~ in ~~line with published data~~. ~~Although the lethal dose of 4F-MDMB-BINACA~~ is ~~unknown, its concentration in postmortem blood samples~~ was ~~found~~ to ~~range between 0~~.10 ~~and~~ 2.~~90 ng/mL .~~ In ~~SCRA-related cases in which~~ the ~~deceased suffered from heart disease~~, ~~the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however~~, ~~some reports of survival have also been published—even at relatively high blood SCRA concentrations [19~~, 20<br><br><br>A limitation of this case report is that we did not have a urine sample available for additional NPS testing. Point-of-care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines and methadone. THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e-cigarettes, while crack cocaine is hard to vaporise. A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours .<br> Data availability <br>Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patient.<br> Data availabili<br><br><br>LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden JWH-210 powder headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl	+	When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC<br><br>4. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>Michael B Gatch <br>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the [https://cannabinoidsrc4f-adb.com/ adb butinaca] highest dose tested (0.5 mg/kg).<br>Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic<br><br>Metabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans <br>This might be due to the low activity of numerous metabolizing enzymes resulting in lower drug biotransformation . HepG2 model detected the major ester hydrolysis metabolite of 4F-MDMB-BINACA in abundance but the rest of the metabolites were found in a small amount. Elegans and HLM models detected all of the in-vivo metabolites (100%), whilst HepG2 cells detected 7 out of the 8 in-vivo metabolites (87.5%). Hence, structural elucidation could not be confirmed unless a reference standard is made availabl<br><br><br>The same procedure was then applied to the mice once every day for 5 days. It was considered as coordination disturbance when mice fell from the test apparatus within 2 min. Mice that remained their position on the running apparatus at 10 rpm for at least 2 min were selected for further evaluation.<br>Table of Conten<br><br>In the present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, and water-maze test for learning/memory evaluatio<br><br><br>A limitation of this case report is that we did not have a urine sample available for additional NPS testing. Point-of-care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines and methadone. THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e-cigarettes, while crack cocaine is hard to vaporise. A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours .<br>Data availability <br>Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patien